Targeting cancer cells and tissue using filamentous plant virus particles
AssigneeCase Western Reserve University
InventorsNicole F. Steinmetz, Sourabh Shukla
Life of this patent
Estimating the term…
Abstract
A pepino mosaic virus (PepMV) carrier comprising a PepMV particle that has been modified to carry an imaging agent or anticancer agent is described. The PepMV carrier can be used in a method of targeting cancer cells and tissue by administering it to a subject. Cancer tissue targeted by the PepMV carrier can be imaged using an imaging agent, or treated using an anticancer agent.
Claims14
A method of targeting cancer tissue in a subject, comprising administering to the subject a pepino mosaic virus (PepMV) carrier comprising a PepMV particle modified to carry an imaging agent or a cytotoxic compound,
- wherein the PepMV carrier targets cancer tissue selected from the group consisting of triple negative breast cancer (TNBC) tissue or ovarian cancer tissue and has increased tumor homing to triple negative breast cancer (TNBC) tissue and to ovarian cancer tissue compared to a potato virus X (PVX) carrier,
- wherein the PepMV carrier is administered via systemic or intraperitoneal (i.p.) administration, and
- wherein the PepMV carrier has 1.5-fold increase in tumor homing in triple negative breast cancer (TNBC) tumors and 2-fold increase in tumor homing in ovarian cancer tumors compared to a potato virus X (PVX) carrier.
A method of treating cancer in a subject identified as having cancer by administering to the subject a therapeutically effective amount of a pepino mosaic virus (PepMV) carrier comprising a PepMV particle modified to carry an anticancer agent,
- wherein the PepMV carrier targets cancer tissue selected from the group consisting of ovarian cancer or triple negative breast cancer (TNBC) and has increased tumor homing to triple negative breast cancer (TNBC) tumors and to ovarian cancer tumors compared to a potato virus X (PVX) carrier,
- wherein the PepMV carrier is administered via systemic or intraperitoneal (i.p.) administration, and
- wherein the PepMV carrier has 1.5-fold increase in tumor homing in triple negative breast cancer (TNBC) tumors and 2-fold increase in tumor homing in ovarian cancer tumors compared to a potato virus X (PVX) carrier.
Dependencies are inferred from the claim text.